CD274 and neoplasm: However, the combination of IL-12 and trabectedin with an anti–PD-L1 significantly reduced tumor growth and volumes beyond that achieved with IL-12 and trabectedin therapy alone and led to one complete response (P = 0.03; Fig. 7A–C).